CoDiagnostics Regains Nasdaq Compliance, Advances PCR Diagnostic Technology Development

CoDiagnostics Achieves Nasdaq Compliance, Set to Advance PCR Platform Development

CoDiagnostics, Inc., a molecular diagnostics company based in Utah, announces its recent compliance with Nasdaq listing requirements as of March 9, 2026. This compliance, crucially meeting the $1.00 bid price rule, allows the company’s shares to resume trading on Nasdaq effective March 11, 2026. Regaining compliance marks a significant development for Co-Diagnostics, particularly as the company aims to enhance its flexibility in capital markets. The successful resolution of its previous listing issues bodes well for shareholder confidence, aligning with the company’s core focus on advancing its innovative diagnostics platform.

Central to Co-Diagnostics’ growth strategy is its Co-Dx PCR point-of-care diagnostics platform, which includes offerings such as the PCR Home™, PCR Pro™, and an integrated mobile application. As these products remain under FDA review and are not yet commercially available, the company emphasizes the importance of completing clinical performance studies for regulatory clearances. The development of advanced diagnostic technologies is paramount for Co-Diagnostics, particularly as it aims to create highly specific tests that identify genetic markers across a spectrum of uses beyond infectious diseases. Achieving compliance with Nasdaq not only facilitates capital raising efforts but also enables Co-Diagnostics to bolster its research and development initiatives in a competitive market.

The press release issued by the company highlights forward-looking statements regarding its future capital market capabilities and objectives for the Co-Dx PCR platform. It underlines the inherent risks and uncertainties that accompany such predictions, advising stakeholders to approach these forecasts with caution. Co-Diagnostics provides comprehensive disclosures regarding potential risks in its Annual Report on Form 10-K filed with the Securities and Exchange Commission. This transparency reflects the company’s commitment to responsible management practices and engaging with its shareholders regarding the intricacies of its operational strategy.

In parallel, the achieved compliance supports Co-Diagnostics' commitment to innovation and agility in the rapidly evolving molecular diagnostics field. The company aims to play a pivotal role in transforming diagnostic capabilities, focusing on unique niches that could lead to significant breakthroughs in health management. As it navigates the complexities of FDA approvals and market readiness, the regained Nasdaq compliance serves not only as a strategic advantage but also as an affirmation of the company's long-term vision in the diagnostics landscape.

With Nasdaq compliance under its belt, CoDiagnostics is poised to leverage this momentum in advancing its diagnostic technology portfolio, ultimately aiming to enhance public health outcomes through precise and timely testing solutions.